Opinion|Videos|May 20, 2024
Approaching Treatment in Hypercortisolism
Panelists review current guidelines for treating hypercortisolism, noting the need for guidelines to align with recent advancements, and share their own clinical practice approaches.
Advertisement
Episodes in this series
Advertisement
Related to this article
End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.
With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.
Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).
Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.
Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).
Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.
A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.
Chronic hypertension in pregnancy was tied to 30% higher odds of critical congenital heart disease in a study of 44 million US births.
Advertisement
Advertisement
Trending on HCPLive
1
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
2
STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD
3
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
4
Common Diuretic Linked to Home Blood Pressure Lowering After Stroke
5